Safeguard Investment Advisory Group LLC acquired a new stake in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,789 shares of the company’s stock, valued at approximately $487,000.
Other large investors also recently bought and sold shares of the company. Frazier Financial Advisors LLC acquired a new position in shares of Merck KGaA in the 2nd quarter worth approximately $25,000. Rakuten Securities Inc. acquired a new position in Merck KGaA in the second quarter worth $27,000. Solstein Capital LLC acquired a new position in Merck KGaA in the second quarter worth $33,000. Burk Holdings LLC bought a new stake in Merck KGaA during the second quarter valued at $39,000. Finally, Bard Associates Inc. acquired a new stake in shares of Merck KGaA during the second quarter worth $60,000. Institutional investors own 0.10% of the company’s stock.
Merck KGaA Stock Performance
Merck KGaA stock opened at $163.21 on Monday. Merck KGaA has a 1 year low of $116.68 and a 1 year high of $175.56. The firm’s 50-day moving average is $162.62 and its 200-day moving average is $148.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. The company has a market cap of $21.09 billion, a P/E ratio of 24.92 and a beta of 0.96.
About Merck KGaA
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Read More
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
